Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$428.14 USD
+9.23 (2.20%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $425.98 -2.16 (-0.50%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALNY 428.14 +9.23(2.20%)
Will ALNY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALNY
Earnings Estimates Rising for Alnylam (ALNY): Will It Gain?
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
ALNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates
Other News for ALNY
JPMorgan Boosts Alnylam (ALNY) Price Target Following Strong Q2 Performance
JP Morgan Raises ALNY Price Target to $475, Maintains Overweight Rating | ALNY Stock News
Alnylam price target raised by $127 at JPMorgan, here's why
Alnylam Pharmaceuticals Inc (ALNY) to Present at Canaccord Genuity 45th Annual Growth ...
Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference | ALNY Stock News